Skip to content

Study · Randomized controlled trial · n = 74 · 2004

2 results

Comparative efficacy and safety of cetrorelix with or without mid-cycle recombinant LH and leuprolide acetate for inhibition of premature LH surges in assisted reproduction.

Sauer MV, Thornton MH 2nd, Schoolcraft W, Frishman GN

Reproductive biomedicine online1 Nov 2004Cited by 41 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women undergoing ovarian stimulation, cetrorelix alone produced significantly lower oestradiol per follicle than the other groups (leuprolide acetate, and cetrorelix with r-hLH).

    In plain wordsIn women undergoing ovarian stimulation, cetrorelix alone gave lower oestradiol per follicle than the other groups, which were leuprolide acetate and cetrorelix with r-hLH.

    Peptide
    Cetrorelix
    Outcome
    DecreaseOestradiol per follicle
    Study

    n = 74

    Comparator
    The other groups: leuprolide acetate, and cetrorelix with r-hLH
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3 mgAs given in this study (human).

    Source sentences

    Summary
    The group treated with cetrorelix alone had a significantly lower concentration of oestradiol per follicle compared with the other groups.
    2 context sentences
    Summary · context
    An open label, randomized, multi-centre study was performed to compare cetrorelix and leuprolide acetate for prevention of premature LH surge and to assess whether patients treated with cetrorelix benefit from addition of recombinant human (r-h)LH.
    Summary · context
    Normo-ovulatory women (n = 74) undergoing ovarian stimulation prior to intracytoplasmic sperm injection were treated with leuprolide acetate (n = 25) before ovarian stimulation with recombinant human FSH (r-hFSH) or with cetrorelix 3 mg on stimulation day 7 (with (n = 25) or without (n = 24) r-hLH 150 IU on days 7-10).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women undergoing ovarian stimulation, leuprolide acetate produced higher oestradiol per follicle than cetrorelix alone.

    In plain wordsIn women undergoing ovarian stimulation, leuprolide acetate produced higher oestradiol per follicle than cetrorelix alone.

    Peptide
    Leuprolide
    Outcome
    IncreaseOestradiol per follicle
    Study

    n: not reported in source

    Comparator
    Cetrorelix alone with background recombinant FSH
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The group treated with cetrorelix alone had a significantly lower concentration of oestradiol per follicle compared with the other groups.
    2 context sentences
    Summary · context
    An open label, randomized, multi-centre study was performed to compare cetrorelix and leuprolide acetate for prevention of premature LH surge and to assess whether patients treated with cetrorelix benefit from addition of recombinant human (r-h)LH.
    Summary · context
    Normo-ovulatory women (n = 74) undergoing ovarian stimulation prior to intracytoplasmic sperm injection were treated with leuprolide acetate (n = 25) before ovarian stimulation with recombinant human FSH (r-hFSH) or with cetrorelix 3 mg on stimulation day 7 (with (n = 25) or without (n = 24) r-hLH 150 IU on days 7-10).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 2

    27 Oct 2026, 16:37 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.